Response to erythropoietic‐stimulating agents in patients with chronic myelomonocytic leukemia

Xicoy, Blanca; Germing, Ulrich; Jiménez, María-José; García, Olga; García, Regina; Schemenau, Jeniffer; Pedro, Carme; Luño, Elisa; Bernal, Teresa; González, Bernardo; Strupp, Corinna; Ardanaz, Maite; Kuendgen, Andrea; Cedena, María-Teresa; Neukirchen, Judith; Calabuig, Marisa; Brunet, Salut; Medina, Ángeles; Amigo, María‐Luz; Ramos, Fernando; Callejas, Marta; Díez-Campelo, María; Bailén, Alicia; Collado, Rosa; Vicente, Ana I.; Arnán, Montserrat; Valcárcel, David; Arilla, M.J.; Zamora, Lurdes; Benlloch, Luis; Sanz, Guillermo

doi:10.1111/ejh.12679

Cited by 26 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies in MDS and chronic myelomonocytic leukemia have established that a lower EPO level is associated with superior responses to ESAs. 31,32 The findings in this study imply that the EPO level, specifically a cutoff of 200 IU/L, may have merit in predicting response to ESAs in AUE in addition to in MDS.…”

Section: Discussionmentioning

confidence: 80%

Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

Gowanlock¹,

Sriram²,

Martin³

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 80%

Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

Gowanlock¹,

Sriram²,

Martin³

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

“…Achievement of ER correlated with a better survival. 152 Challenging neutropenia is extremely infrequent in untreated CMML. Severe neutropenia in patients treated with cytoreductive drugs should be addressed by tapering and/or interrupting the drug.…”

Section: Treatmentmentioning

confidence: 99%

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Itzykson

Fenaux

Bowen³

et al. 2018

HemaSphere

Self Cite

102

View full text Add to dashboard Cite

Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults. Aside from the chronic monocytosis that remains the cornerstone of its diagnosis, the clinical presentation of CMML includes dysplastic features, cytopenias, excess of blasts, or myeloproliferative features including high white blood cell count or splenomegaly. Prognosis is variable, with several prognostic scoring systems reported in recent years, and treatment is poorly defined, with options ranging from watchful waiting to allogeneic stem cell transplantation, which remains the only curative therapy for CMML. Here, we present on behalf of the European Hematology Association and the European LeukemiaNet, evidence- and consensus-based guidelines, established by an international group of experts, from Europe and the United States, for standardized diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with CMML.

show abstract

“…In lower-risk CMML, treatment of anemia can rely on Erythropoiesis Stimulating Agents (ESAs) with MDS regimens [65], whereas thrombopoietin agonists seem more difficult to use, and still require prospective evaluation [66]. In patients with proliferative features, hydroxyurea remains a standard of care [2].…”

Section: Treatmentmentioning

confidence: 99%

CMML: Clinical and molecular aspects

et al. 2017

View full text Add to dashboard Cite

Response to erythropoietic‐stimulating agents in patients with chronic myelomonocytic leukemia

Abstract: The CPSS and EPO levels are adequate tools to select CMML patients with symptomatic anemia who may benefit from treatment with ESA. A significant ER to ESA is expected in anemic patients with low/intermediate-1 CMML risk by the CPSS and a low endogenous serum EPO level.

Cited by 26 publications

References 28 publications

Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

CMML: Clinical and molecular aspects

Contact Info

Product

Resources

About